|
ImmunoGen is TAPping into cancer research. The firm's product candidates are TAPs, or tumor-activated prodrugs, that combine cancer-killing drugs with monoclonal antibodies and attach only to tumor cells. On its own, ImmunoGen is developing two clinical-stage compounds: IMGN242, a TAP drug candidate to treat gastrointestinal cancers and some non-small-cell lung cancers; and IMGN901, which targets small-cell lung cancer and multiple myeloma. The firm has additional candidates in clinical trials through partnerships with Genentech and Sanofi-Aventis, and it has outlicensed its TAP technology to the likes of Biogen Idec and Centocor.
|
| | | Contact Information | |
Address: |
830 Winter St.
Waltham, MA 02451-1477
| | Phone: | 781-895-0600 | | Fax: | 781-895-0611 |
|
| Financial
Highlights | | Fiscal Year End: | June | | Revenue (2009): | 28.00 M | | Revenue Growth (1 yr): | (-30.50%) | | Employees (2009): | 210 | | Employee Growth (1 yr): | 0.00% |
|
|
Key People
| | • |
Chairman:
Stephen C. McCluski
| | • |
President, CEO, and Director:
Daniel M. (Dan) Junius
| | • |
SVP and CFO:
Gregory D. (Greg) Perry
|
|
|
